Evaluation of the antidepressant, anxiolytic and memory-improving efficacy of aripiprazole and fluoxetine in ethanol-treated rats

Drug and Chemical Toxicology

Volumn 37, Issue 3, 2014, Pages 281-289

  Burda Malarz, Kinga ^a   Kus, Krzysztof ^a   Ratajczak, Piotr ^a   Czubak, Anna ^a   Hardyk, Szymon ^a   Nowakowska, Elzbieta ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Atypical antipsychotic; Cognitive function; Ethanol dependence

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; FLUOKETSYNA; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; NONHUMAN; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SPATIAL MEMORY; TRANQUILIZING ACTIVITY; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; MALE; MAZE TEST; SWIMMING; TOXICITY; WISTAR RAT;

ALCOHOLISM; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DRUG THERAPY, COMBINATION; ETHANOL; FLUOXETINE; MALE; MAZE LEARNING; PIPERAZINES; QUINOLONES; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; SPATIAL MEMORY; SWIMMING;

EID: 84901926042     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480545.2013.851687     Document Type: Article

References (43)

1. Beatty WW, Katzung VM, Moreland VJ, Noxon SJ. (1995). Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend 37:247-253.
2. Berk M, Dodd S, Kauer-Sant'anna M, Hascoet M. (2007). Dopamine disregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 434:41-49. (Pubitemid 47241063)
3. Bourin M, Chenu F, Prica C, et al. (2009). Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology 206:97-107.
4. Burda K, Czubak A, Kus K, et al. (2011). Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep 63:898-907.
5. Burris KD, Molski TF, Xu C, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389. (Pubitemid 34680462)
6. Conway KP, Compton W, Stinson FS, Grant BF. (2006). Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug of use disorders: results from the National Epidemiologic Survey on Alcohol and Releated Conditions. J Clin Psychiatry 67:247-257. (Pubitemid 43357471)
7. Crawley JN. (1981). Neuropharmacologic specificity of simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15:695-699. (Pubitemid 12195249)
8. Di Chiara G, Imperato A. (1985). Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur J Pharmacol 115:131-132. (Pubitemid 16233374)
9. Egashira N, Okuno R, Matsushita M, et al. (2008). Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor- independent mechanisms. Eur J Pharmacol 592:103-108.
10. Enomoto T, Ishibashi T, Tokuda K, et al. (2008). Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 186: 197-207. (Pubitemid 350122756)
11. Gessa GL, Muntoni F, Collu M, et al. (1985). Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 348:201-203. (Pubitemid 16235764)
12. Ilgen M, Moos R. (2005). Deterioration following alcohol use disorder treatment in Project MATCH. J Stud Alcohol Drugs 66:517-525. (Pubitemid 41193159)
13. Ishiyama T, Tokuda K, Ishibashi T, et al. (2007). Lurasidone (SM- 13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572:160-170. (Pubitemid 47429645)
14. Jordan S, Koprivica V, Chen R, et al. (2002). The antipsychotic aripiprazole is a potent, partial agonist at human 5-HT1A receptor. Eur J Pharmacol 441:137-140. (Pubitemid 34626163)
15. Kamei J, Miyata S, Sunohara T, et al. (2008). Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test. J Pharmacol Sci 108:381-384.
16. Kessler RC, Crum RM, Warner LA, et al. (1997). Lifetime cooccurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 54:313-321. (Pubitemid 27171916)
17. Lal H, Prather PL, Rezazadeh SM. (1993). Potential role of 5HT1C and/ or 5HT2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol Clin Exp Res 17:411-417. (Pubitemid 23135454)
18. Li Z, Ichikawa J, Dai J, Meltzer HY. (2004). Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493: 75-83. (Pubitemid 38746934)
19. Maj J, Rogoz Z. (1999). Synergistic effect of pramipexole and sertraline in the forced swimming test. Pol J Pharmacol 51:471-475. (Pubitemid 30052667)
20. Marder SR, McQuade RD, Stock E, et al. (2003). Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123-136. (Pubitemid 36513927)
21. Mikołajczak P, Okulicz-Kozaryn I, Kaminska E, et al. (2003). Lack of ifenprodil anxiolytic activity after its multiple treatment in chronically ethanol-treated rats. Alcohol Alcohol 38:310-315. (Pubitemid 36826977)
22. Morley JE, Thomas DR, Wilson MM. (2006). Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735-743. (Pubitemid 44713134)
23. Morris R. (1984). Development of a water-maze procedure for studying spatial learning in a rat. J Neurosci Methods 11:47-60. (Pubitemid 14088970)
24. Nordmann R. (1994). Alcohol and antioxidant systems. Alcohol 29: 513-522. (Pubitemid 24296305)
25. Nowakowska E, Chodera A, Kus K. (1996). Anxiolytic and memory improving activity of fluoxetine. Pol J Pharmacol 48:255-260. (Pubitemid 26294782)
26. Nowakowska E, Kus K, Chodera A, Rybakowski J. (2000). Behavioural effects of fluoxetine and tianeptine, two antidepressants with opposite action mechanisms, in rats. Arzneimittelforschung 50: 5-10. (Pubitemid 30062501)
27. Okulicz-Kozaryn I, Mikołajczak P, Kamin'ska E, et al. (2004). Effect of naltrexone administration on short-term memory in chronically ethanol-treated outbred rats. Alcohol Alcohol 39:14-19. (Pubitemid 38111666)
28. Pae CU, Serretti A, Patkar AA. (2008). Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 22:367-388. (Pubitemid 351508122)
29. Porsolt RD, Anton G, Blavet N, Jalfre M. (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391.
30. Potkin SG, Saha AR, Kujawa MJ, et al. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690. (Pubitemid 36818630)
31. Preskorn SH. (2003). Relating clinical trials to psychiatric practice: part I: the case of a 13-year old on aripiprazole and fluoxetine. J Psychiatr Pract 9:307-313. (Pubitemid 36909898)
32. Ratti MT, Giardini A, Soragna D. (2002). Chronic alcoholism and the frontal lobe: which executive functions are impaired? Acta Neurol Scand 105:276-281 (Pubitemid 34407230)
33. Renard CE, Dailly E, David DJ, et al. (2003). Neurochemical changes following the mouse forced swimming test but not the tail suspension test. Int J Neuropsychopharmacol 17:449-455. (Pubitemid 36920646)
34. Renard CE, Dailly E, Nic Dhonnchadha BA, et al. (2004). Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test? Prog Neuropsychopharmacol Biol Psychiatry 28: 1255-1259 (Pubitemid 39592922)
35. Renard CE, Fiocco AJ, Clenet F, et al. (2001). Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology 159: 42-50 (Pubitemid 34031249)
36. Sachs GS, Sanchez R, Marcus RN, et al. (2006). Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 20: 536-546. (Pubitemid 43875183)
37. Semba J, Watanabe A, Kito S, Toru M. (1995). Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34: 785-791.
38. Silva MTA, Alves CRR, Santarem EMM. (1999). Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plusmaze. Brazil J Med Biol Res 32:333-339. (Pubitemid 29169305)
39. Sullivan EV, Deshmukh A, De Rosa E, et al. (2005). Striatal and forebrain nuclei volumes: contribution to motor function and working memory deficits in alcoholism. Biol Psychiatry 57:768-776. (Pubitemid 40487921)
40. Vieta E, Bourin M, Sanchez R, et al.; Aripoprazole Study Group. (2005). Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomized, comparative 12-week trial. Br J Psychiatry 187:235-242. (Pubitemid 41306104)
41. Weiss F, Porrino LJ. (2002). Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 22:3332-3337. (Pubitemid 37465737)
42. Yatham LN, Goldstein JM, Vieta E, et al. (2005). Atypical antipsychotic in bipolar depression: potential mechanism of action. J Clin Psychiatry 66:40-48. (Pubitemid 40934073)
43. Zhang Y, Raap DK, Garcia F, et al. (2000). Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Res 855:58-66. (Pubitemid 30067694)